GuideAI Health vs Nucs AI (2026)
Two narrow imaging companies built around a single disease each, which is a legitimate strategy in a field where general purpose detection struggles to prove value. GuideAI detects peripheral vascular disease from CT, aimed at a condition that is routinely present and routinely unremarked on scans taken for other reasons. Nucs covers the prostate cancer pathway around specialised imaging, with several products spanning automated analysis and the theranostics workflow. Neither competes with the other clinically, and a department would choose based on which service line it is trying to strengthen. What both should be asked, and neither publishes, is the false positive rate in a consecutive unselected series. In opportunistic detection the specificity number decides everything, because every false positive becomes someone else's follow up appointment.
- It targets peripheral vascular disease from CT imaging, a condition routinely underdiagnosed because nobody is looking for it on scans taken for other reasons.
- Radiologist founded, with the triage software aimed at a specific vascular pathway rather than at general findings.
- For a vascular service, a tool pointed at the disease you treat is more useful than a broad finding detector.
- It covers a whole cancer pathway rather than one finding, spanning automated organ and lesion work in prostate imaging and the theranostics workflow around it.
- Depth in one disease across several products means the outputs connect rather than each standing alone.
- For a prostate cancer service running specialised imaging, a pathway product fits the way that service actually works.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. GuideAI Health and Nucs AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | GuideAI Health | Nucs AI |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2023 | 2024 |
| Headquarters | Boston, Massachusetts, United States | New York, New York, United States |
| Website | guideaihealth.com | nucs.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards GuideAI Health its top capability grade on AI Centrality, Autonomy and Oversight Model and FDA and Regulatory Status. Set against Nucs AI, GuideAI Health grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and FDA and Regulatory Status. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Nucs AI its top capability grade on AI Centrality. Set against GuideAI Health, Nucs AI grades higher on Model Supply Chain Disclosure. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose GuideAI Health or Nucs AI?
On the axes where the AI Health Index separates them, GuideAI Health grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and FDA and Regulatory Status, and Nucs AI grades higher on Model Supply Chain Disclosure. GuideAI Health leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do GuideAI Health and Nucs AI differ most?
The widest separation the AI Health Index records between GuideAI Health and Nucs AI is on FDA and Regulatory Status, where GuideAI Health grades A and Nucs AI grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do GuideAI Health and Nucs AI grade the same?
The AI Health Index grades GuideAI Health and Nucs AI the same on several axes, including AI Centrality, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have GuideAI Health and Nucs AI not disclosed?
At the last review, at least one of GuideAI Health and Nucs AI published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both are narrow single disease imaging products and neither publishes the figure that determines whether such a product is usable at scale: the false positive rate in a routine population rather than in a validation cohort enriched with disease. In opportunistic detection the clinical burden lands on whoever must work up the findings, and a specificity shortfall at population scale generates far more work than the detection saves. Neither publishes pricing, a security attestation or a subgroup performance analysis. Ask both for performance in a consecutive unselected series rather than in a curated dataset.